勵晶太平洋(00575.HK):治療早泄處方藥Fortacin已在香港推出 並積極在亞洲其他國家推出
格隆匯1月18日丨勵晶太平洋(00575.HK)發佈公吿,集團於台灣、香港特別行政區、澳門特別行政區及其他亞洲選定地區的商業戰略伙伴友華生技醫藥股份有限公司,自本月起已在香港推出銷售集團用以治療早泄的處方藥Fortacin。
友華生技醫藥同時知會集團,其預計於2021年3月及4月分別在澳門及台灣(其本土市場)推出Fortacin。集團將會按友華生技醫藥於該等市場的淨銷售額收取低雙位數的特許權使用費。這對集團而言是一個至關重要的時刻,概因集團在其本土市場香港提供Fortacin的戰略目標透過友華生技醫藥得以實現。
公司行政總裁Jamie Gibson表示:在香港推出及即將在其他亞洲國家推出Fortacin可進一步鞏固公司於該地區早泄治療領域的領導地位。更為重要的是,憑藉在亞洲地區廣泛覆蓋,公司在不久將來於快速增長的全球早泄治療市場佔據主要份額處於領先位置。
集團同時欣然知會股東,公司於中國的商業戰略伙伴江蘇萬邦生化醫藥集團有限責任公司已委聘一間領先的合同研究機構,在中國進行隨機化臨牀試驗。待取得國家藥品監督管理局的批准後,隨機化臨牀試驗計劃將於2021年四月份╱五月份隨即展開。
此外,集團目前正與一名潛在夥伴展開初步商討,以就日本市場將Fortacin的權利。儘管該等進展着實令人振奮,但目前尚無法確定完成有關商討的準確時間,亦不能保證經有關商討後將會訂立具約束力的特許協議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.